The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Ivacaftor potentiation of multiple CFTR channels with gating mutations
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA
Riordan, J. R., Rommens, J. M., Kerem, B.-S., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.-L., et al. (1989) · Science · doi:10.1126/science.2475911 · Cited by 7,418
Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis
Welsh, M. J., & Smith, A. E. (1993) · Cell · doi:10.1016/0092-8674(93)90353-r · Cited by 1,485
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A., Joubran, J., Hazlewood, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904709106 · Cited by 1,228
Self-citationBobadilla, J. L., Macek, M., Fine, J. P., & Farrell, P. M. (2002) · Human Mutation · doi:10.1002/humu.10041 · Cited by 1,032
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- CFTR Mutation
Accurso, F. J., Rowe, S. M., Clancy, J. P., Boyle, M. P., Dunitz, J. M., Durie, P. R., Sagel, S. D., Hornick, D. B., Konstan, M. W., Donaldson, S. H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909825 · Cited by 807
Davis, P. B., Drumm, M., & Konstan, M. W. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.154.5.8912731 · Cited by 764
Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice
Castellani, C., Cuppens, H., Macek, M., Cassiman, J. J., Kerem, E., Durie, P., Tullis, E., Assael, B. M., Bombieri, C., Brown, A., et al. (2008) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.03.009 · Cited by 601
Mutations in CFTR associated with mild-disease-form CI- channels with altered pore properties
Sheppard, D. N., Rich, D. P., Ostedgaard, L. S., Gregory, R. J., Smith, A. E., & Welsh, M. J. (1993) · Nature · doi:10.1038/362160a0 · Cited by 467
Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study
McKone, E. F., Emerson, S. S., Edwards, K. L., & Aitken, M. L. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13368-5 · Cited by 397
Cystic fibrosis: a disease of vulnerability to airway surface dehydration
Boucher, R. C. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.05.001 · Cited by 273
Regulation by ATP and ADP of CFTR Chloride Channels That Contain Mutant Nucleotide-Binding Domains
Anderson, M. P., & Welsh, M. J. (1992) · Science · doi:10.1126/science.1382316 · Cited by 233
Gating of the CFTR Cl− channel by ATP‐driven nucleotide‐binding domain dimerisation
Hwang, T., & Sheppard, D. N. (2009) · The Journal of Physiology · doi:10.1113/jphysiol.2009.171595 · Cited by 170
Zielenski, J., Bozon, D., Kerem, B.-S., Markiewicz, D., Durie, P., Rommens, J. M., & Tsui, L.-C. (1991) · Genomics · doi:10.1016/0888-7543(91)90504-8 · Cited by 166
Pedemonte, N., Sonawane, N. D., Taddei, A., Hu, J., Zegarra‐Moran, O., Suen, Y. F., Robins, L. I., Dicus, C. W., Willenbring, D., Nantz, M. H., et al. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.010959 · Cited by 146
Morán, Ó., Galietta, L. J. V., & Zegarra‐Moran, O. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4422-3 · Cited by 122
Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein
Illek, B., Zhang, L., Lewis, N. C., Moss, R. B., Dong, J.-Y., & Fischer, H. (1999) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1999.277.4.c833 · Cited by 121
He, L., Aleksandrov, A. A., Serohijos, A. W. R., Hegedűs, T., Aleksandrov, L. A., Cui, L., Dokholyan, N. V., & Riordan, J. R. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803894200 · Cited by 117
Seibert, F. S., Linsdell, P., Loo, T. W., Hanrahan, J. W., Riordan, J. R., & Clarke, D. M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.44.27493 · Cited by 104
Cai, Z., Taddei, A., & Sheppard, D. N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m510576200 · Cited by 98
Insight in eukaryotic ABC transporter function by mutation analysis
Frelet‐Barrand, A., & Klein, M. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.01.024 · Cited by 94
Fulmer, S. B., Schwiebert, E. M., Morales, M. M., Guggino, W. B., & Cutting, G. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.6832 · Cited by 79
Seibert, F. S., Jia, Y., Mathews, C. J., Hanrahan, J. W., Riordan, J. R., Loo, T. W., & Clarke, D. M. (1997) · Biochemistry · doi:10.1021/bi9712652 · Cited by 77
Pedemonte, N., Diena, T., Caci, E., Nieddu, E., Mazzei, M., Ravazzolo, R., Zegarra‐Moran, O., & Galietta, L. J. V. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.015149 · Cited by 58
Caputo, A., Hinzpeter, A., Caci, E., Pedemonte, N., Arous, N., Duca, M. D., Zegarra‐Moran, O., Fanen, P., & Galietta, L. J. V. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.154146 · Cited by 34
Clinical phenotype of cystic fibrosis patients with the G551D mutation
Comer, D., Ennis, M., McDowell, C., Beattie, D., Rendall, J. C., Hall, V., & Elborn, J. S. (2009) · QJM · doi:10.1093/qjmed/hcp120 · Cited by 30
Oene, M. V., Lukács, G. L., & Rommens, J. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002186200 · Cited by 14
Storm, K., Moens, E., Vits, L., Vlieger, H. D., Delaere, G., D'Hollander, M., Wuyts, W. A., Biervliet, M., Schil, L. V., Desager, K., et al. (2007) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2006.10.013 · Cited by 8
Cited by
Elborn, J. S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00576-6 · Cited by 1,805
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
Wainwright, C. E., Elborn, J. S., Ramsey, B. W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J. C., De Boeck, K., Flume, P. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409547 · Cited by 1,622
The future of cystic fibrosis care: a global perspective
Bell, S. C., Mall, M. A., Gutierrez, H., Macek, M., Madge, S., Davies, J. C., Burgel, P.-R., Tullis, E., Castaños, C., Castellani, C., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30337-6 · Cited by 974
Cystic fibrosis genetics: from molecular understanding to clinical application
Cutting, G. R. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3849 · Cited by 965
Opportunities and challenges in phenotypic drug discovery: an industry perspective
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.111 · Cited by 939
Metadata
- Authors
- Yu, H., Burton, B., Huang, C.-J., Worley, J., Cao, D., Johnson, J. P., Urrutia, A., Joubran, J., Seepersaud, S., Sussky, K., Hoffman, B. J., & Van Goor, F.
- Venue
- Journal of Cystic Fibrosis
- Publisher
- Elsevier BV
- Published
- 2012-05
- Volume
- 11
- Issue
- 3
- Pages
- 237-245
- ISSN
- 1569-1993 (ISSN-L)
- OpenAlex
- W1976197028
- Cited by
- 423
- References
- 27
- FWCI
- 31.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.